MXPA02001813A - Hydroxyalkanoyl aminolactams and related structures as inhibitors of a beta protein production. - Google Patents
Hydroxyalkanoyl aminolactams and related structures as inhibitors of a beta protein production.Info
- Publication number
- MXPA02001813A MXPA02001813A MXPA02001813A MXPA02001813A MXPA02001813A MX PA02001813 A MXPA02001813 A MX PA02001813A MX PA02001813 A MXPA02001813 A MX PA02001813A MX PA02001813 A MXPA02001813 A MX PA02001813A MX PA02001813 A MXPA02001813 A MX PA02001813A
- Authority
- MX
- Mexico
- Prior art keywords
- aminolactams
- hydroxyalkanoyl
- inhibitors
- protein production
- related structures
- Prior art date
Links
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 abstract 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000003951 lactams Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
This invention relates to novel lactams having formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Abgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to bgr;-amyloid production such as Alzheimer s disease and Down s Syndrome.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15351199P | 1999-09-13 | 1999-09-13 | |
| US22438800P | 2000-08-09 | 2000-08-09 | |
| PCT/US2000/024967 WO2001019797A2 (en) | 1999-09-13 | 2000-09-13 | HYDROXYALKANOYL AMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02001813A true MXPA02001813A (en) | 2004-03-19 |
Family
ID=26850619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02001813A MXPA02001813A (en) | 1999-09-13 | 2000-09-13 | Hydroxyalkanoyl aminolactams and related structures as inhibitors of a beta protein production. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1212306A2 (en) |
| JP (1) | JP2003509411A (en) |
| CN (1) | CN1399634A (en) |
| AU (1) | AU783914B2 (en) |
| BR (1) | BR0014269A (en) |
| CA (1) | CA2377221A1 (en) |
| IL (1) | IL147774A0 (en) |
| MX (1) | MXPA02001813A (en) |
| WO (1) | WO2001019797A2 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6960576B2 (en) | 1999-09-13 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production |
| ES2275675T3 (en) | 2000-03-23 | 2007-06-16 | Elan Pharmaceuticals, Inc. | COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE. |
| AU2001253108A1 (en) | 2000-04-03 | 2001-10-15 | Bristol-Myers Squibb Pharma Company | Cyclic lactams as inhibitors of a-beta protein production |
| CA2404273A1 (en) * | 2000-04-11 | 2001-10-18 | Bristol-Myers Squibb Pharma Company | Substituted lactams as inhibitors of a.beta. protein production |
| AU2001261728A1 (en) | 2000-05-17 | 2001-11-26 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands for diagnostic imaging |
| GB0012671D0 (en) | 2000-05-24 | 2000-07-19 | Merck Sharp & Dohme | Therapeutic agents |
| CN1386118A (en) | 2000-06-01 | 2002-12-18 | 布里斯托尔-迈尔斯斯奎布药品公司 | Lactams substituted by cyclic succinates as inhibitors of A beta protein production |
| PE20020276A1 (en) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | SUBSTITUTE AMINE COMPOUNDS AS ß-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER |
| ES2252257T3 (en) | 2000-06-30 | 2006-05-16 | Elan Pharmaceuticals, Inc. | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE. |
| US6846813B2 (en) | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
| EP1666452A2 (en) | 2000-06-30 | 2006-06-07 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
| CA2452039A1 (en) | 2001-06-27 | 2003-01-09 | Elan Pharmaceuticals, Inc. | Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease |
| WO2003055850A1 (en) * | 2001-12-27 | 2003-07-10 | Daiichi Pharmaceutical Co., Ltd. | β-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS |
| AU2003229024A1 (en) | 2002-05-07 | 2003-11-11 | Elan Pharmaceuticals, Inc. | Succinoyl aminopyrazoles and related compounds |
| TW200502221A (en) * | 2002-10-03 | 2005-01-16 | Astrazeneca Ab | Novel lactams and uses thereof |
| WO2005009344A2 (en) | 2003-06-05 | 2005-02-03 | Elan Pharmaceuticals, Inc. | Acylated amino acid amidyl pyrazoles and related compounds |
| CA2676715A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| EP2146722A4 (en) | 2007-05-10 | 2011-08-03 | Amr Technology Inc | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| EP2489656A1 (en) | 2007-12-21 | 2012-08-22 | Ligand Pharmaceuticals Inc. | Selective androgen receptor modulators (sarms) and uses thereof |
| WO2009128057A2 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
| EP3094323A4 (en) | 2014-01-17 | 2017-10-11 | Ligand Pharmaceuticals Incorporated | Methods and compositions for modulating hormone levels |
| CA3133929A1 (en) | 2019-04-19 | 2020-10-22 | Lin Zhi | Crystalline forms and methods of producing crystalline forms of a compound |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
| KR20000069075A (en) * | 1996-11-22 | 2000-11-25 | 진 엠. 듀발 | N-(Aryl/Heteroaryl/Alkylacethyl)Amino Acid Amides, Pharmaceutical Compositions Comprising Same, and Methods for Inhibiting Beta-Amyloid Peptide Release and/or its Synthesis by Use of Such Compounds |
| JP3812952B2 (en) * | 1996-12-23 | 2006-08-23 | エラン ファーマシューティカルズ，インコーポレイテッド | Cycloalkyl, lactam, lactone and related compounds and pharmaceutical compositions thereof, and methods of inhibiting the release of β-amyloid peptide and / or synthesis thereof using the compounds |
| BR9812773A (en) * | 1997-12-22 | 2000-10-10 | Elan Pharm Inc | "polycyclic alpha-amino-epsilon-caprolactams and related compounds" |
| AU4710499A (en) | 1998-06-22 | 2000-01-10 | Elan Pharmaceuticals, Inc. | Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use ofsuch compounds |
| HRP990246A2 (en) | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
| BR9917082A (en) | 1998-12-24 | 2001-11-06 | Du Pont Pharm Co | Compounds that inhibit the production of "beta" proteins, a method of treating neurological disorders associated with the production of "beta" -amyloid, pharmaceutical composition and, method of inhibiting y-secretase activity |
-
2000
- 2000-09-13 MX MXPA02001813A patent/MXPA02001813A/en unknown
- 2000-09-13 AU AU74797/00A patent/AU783914B2/en not_active Ceased
- 2000-09-13 JP JP2001523377A patent/JP2003509411A/en active Pending
- 2000-09-13 IL IL14777400A patent/IL147774A0/en unknown
- 2000-09-13 WO PCT/US2000/024967 patent/WO2001019797A2/en not_active Ceased
- 2000-09-13 EP EP00963374A patent/EP1212306A2/en not_active Withdrawn
- 2000-09-13 CA CA002377221A patent/CA2377221A1/en not_active Abandoned
- 2000-09-13 CN CN00812784A patent/CN1399634A/en active Pending
- 2000-09-13 BR BR0014269-7A patent/BR0014269A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU783914B2 (en) | 2005-12-22 |
| CN1399634A (en) | 2003-02-26 |
| CA2377221A1 (en) | 2001-03-22 |
| IL147774A0 (en) | 2002-08-14 |
| WO2001019797A2 (en) | 2001-03-22 |
| EP1212306A2 (en) | 2002-06-12 |
| BR0014269A (en) | 2002-07-02 |
| JP2003509411A (en) | 2003-03-11 |
| WO2001019797A3 (en) | 2002-04-11 |
| AU7479700A (en) | 2001-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA02001813A (en) | Hydroxyalkanoyl aminolactams and related structures as inhibitors of a beta protein production. | |
| CA2379445A1 (en) | Lactams substituted by cyclic succinates as inhibitors of a.beta. protein production | |
| WO2000038618A3 (en) | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | |
| WO2001060826A3 (en) | SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | |
| TR200100377T2 (en) | Sucinoylamino lactams as Aß Protein production inhibitors. | |
| WO2003027068A3 (en) | Substituted amines for the treatment of neurological disorders | |
| TW200502221A (en) | Novel lactams and uses thereof | |
| TW200512195A (en) | Benzamide 2-hydroxy-3-diaminoalkanes | |
| MXPA04003245A (en) | Hydroxypropylamines. | |
| TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
| MXPA04000328A (en) | Statine derivatives for the treatment of alzheimer's disease. | |
| WO2004022523A3 (en) | 1, 3-diamino-2-hydroxypropane prodrug derivatives | |
| NO961326L (en) | Inhibitors of -amyloid protein production | |
| TNSN04017A1 (en) | N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds | |
| TW200505828A (en) | Substituted ureas and carbamates useful in the treatment of alzheimer's disease | |
| MXPA04000338A (en) | Diaminediols for the treatment of alzheimer's disease. | |
| TW200505418A (en) | Phenacyl 2-hydroxy-3-diaminoalkanes | |
| CA2501799A1 (en) | Pyrazole compounds for treatment of neurodegenerative disorders | |
| MXPA03011521A (en) | Aminediols as agents for the treatment of alzheimer's disease. | |
| YU94103A (en) | Novel sulfonic acid derivatives | |
| MXPA03011466A (en) | Macrocycles useful in the treatment of alzheimer's disease. | |
| BG104983A (en) | Aryl fused azapolycyclic compounds | |
| WO2006026204A3 (en) | Novel gamma-lactams as beta-secretase inhibitors | |
| MXPA03011502A (en) | Substituted aminoalcohols useful in treatment of alzheimer's disease. | |
| TW200504036A (en) | Novel lactams and uses thereof |